MagForce AG Receives FDA Investigational Device Exemption Approval to Conduct a Clinical Trial with NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer
MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc., announces that it has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to conduct a clinical trial with NanoTherm therapy as focal ablation treatment for intermediate risk prostate cancer.
The approval of this IDE now allows MagForce to conduct a pivotal clinical evaluation with the Company's innovative NanoTherm therapy at selected medical centers in the US. MagForce anticipates to initiate patient enrollment in this study in the coming months.
The purpose of this focal thermal ablation registration study that will enroll up to 120 men in a single arm study is to demonstrate that NanoTherm can focally ablate cancer lesions for patients who have advanced to intermediate risk prostate cancer stage and are under active surveillance. By focally ablating these cancer lesions, it is anticipated that patients will be able to be maintained in Active Surveillance Programs and to avoid definitive therapies such as surgery or whole gland radiation with their well-known side effects.
Barbara von Frankenberg, +49-30-308380-77
Communications & Investor Relations
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
NC-LENOVO-NCTA21.2.2019 00:40:10 | Pressemeddelelse
Lenovo Delivers Strong Performance with Highest Quarterly Revenue in Four Years and Record Pre-Tax Income
CGLYTICS20.2.2019 20:12:05 | Pressemeddelelse
In Preparation for the 2019 Proxy Season, CGLytics Expands Global Coverage and Appoints New Head of Research
SIA20.2.2019 16:32:03 | Pressemeddelelse
Payments Canada Selects SIA As the Application Provider for Canada’s New High-Value Payments System, Lynx
ARCH-CAPITAL20.2.2019 16:12:11 | Pressemeddelelse
Arch Capital Group Ltd. Names Janice Englesbe Senior Vice President, Chief Risk Officer
CA-INGRAM-MICRO20.2.2019 16:02:10 | Pressemeddelelse
Ingram Micro and MassChallenge Name Comet Competition Top B2B Startups
TX-KCI20.2.2019 15:32:06 | Pressemeddelelse
KCI Launches ABTHERA™ Therapy in Japan
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum